Clinical Trial for Triple-Negative Breast Cancer
A multicenter clinical trial led by Dr. Saranya Chumsri, assistant professor of Medicine at the University of Maryland School of Medicine and oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women. The study will help researchers determine if an experimental drug, entinostat, can reprogram tumor cells to express a protein molecule called an estrogen receptor to make them sensitive to hormone therapy.
In this three-minute video, breast cancer researchers from UMGCC, including Dr. Chumsri and Dr. Angela Brodie, discuss the importance of this clinical trial and the implications its results could have on the future treatment of triple-negative breast cancer patients.
This page was last updated: September 5, 2014